MK-1248

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-1248, covering 2019-11-04 to 2019-11-04. Get the full timeline:

Most recent: Clinical Trial Update: Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) [Phase 1]

See pricing